As per the research report, the Europe Infectious Diseases Diagnostics Market Size is anticipated to grow at a 7.34% CAGR from 2019 to 2024 and it is estimated that the Europe market was valued at USD 4.38 billion in 2019 and is relied upon to achieve USD 6.24 billion by 2024 during the forecast period 2019-2024.
Infectious disease diagnostics involves various method to check for the presence of foreign antigen/organism with the help of numerous diagnostic tools. Infectious disease conditions are highly widespread in under developed regions owing to the lack of awareness for personal hygiene, minimal health care expenditures, and absence of efficient physician services. Rising cases of infectious diseases in developed economies is further expected to boost the market growth. This has lead vitro diagnostic device manufacturers to invest into emerging economies. These companies are taking efforts to develop and commercialize cost effective tools for the infectious disease diagnosis.
Disease diagnostics are used for confirmation of a disease in form of a quick, precise test result. Being time consuming, disease diagnostics are on a rise. The infectious disease epidemics are spreading worldwide, thereby leading to an increase in demand of diagnostic tests. In addition, the incidences of malaria, flu, AIDS, and other diseases are also on a rise, creating a robust demand for infectious disease diagnostics. With a majority of physicians adopting the evidence-based treatment method, infectious disease diagnostic kits are more likely to gain traction over the forecast period. Several government-funded programs all over the globe are increasingly providing free screening and tests in order to increase awareness, accurately diagnose diseases, and minimize the chances of infection. Such initiatives are anticipated to boost the market growth in the next few years. However, diagnostic kits are expensive and manufacturers still have a poor distribution channel for operating across emerging economies. These two factors are projected to be the key challenges to rapid revenue growth of the global infectious diseases diagnostics market.
This research report segmented and sub-segmented into the following categories:
Europe held the second largest share of the IDD market. This region is projected to witness a single-digit growth rate during the coming years due to growing adoption of premium diagnostic techniques that would sustain the market share of infectious disease diagnostics in developed region.
Key players operating in the Europe Infectious Diseases Diagnostics Market profiled in this report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, SBecton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Instruments & Analyzers
5.1.3 Consumables
5.1.3.1 Assays and Reagents
5.1.4 Services & Softwares
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Technique
5.2.1 Introduction
5.2.2 Traditional Diagnostic Techniques
5.2.2.1 Immunodiagnostics
5.2.2.2 Microscopy
5.2.2.3 Biochemical Characterization
5.2.3 Molecular Diagnostics
5.2.3.1 PCR
5.2.3.2 INAAT
5.2.3.2 Hybridization
5.2.3.3 DNA Sequencing & NGS
5.2.3.4 Microarray
5.2.3.5 Others
5.2.4 Y-o-Y Growth Analysis, By Technique
5.2.5 Market Attractiveness Analysis, By Technique
5.2.6 Market Share Analysis, By Technique
5.3 Application
5.3.1 Introduction
5.3.2 Hepatitis B
5.3.3 Hepatitis C
5.3.4 Human Immunodeficiency Virus (HIV)
5.3.5 Tuberculosis (TB)
5.3.6 Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG)
5.3.7 Human papillomavirus (HPV)
5.3.8 Methicillin-resistant Staphylococcus aureus (MRSA)
5.3.9 Others
5.3.10 Y-o-Y Growth Analysis, By Application
5.3.11 Market Attractiveness Analysis, By Application
5.3.12 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Hospitals Laboratories
5.4.3 Physician office Labs
5.4.4 Academics
5.4.5 Others
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Technique
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Technique
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Technique
6.1.5.4 By Application
6.1.5.5 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 bioMérieux SA &
Related Reports
Feb 2020
Download Sample
